Insulin glargine use and breast cancer risk: Associations with cumulative exposure

References

• Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies BMJ 2015;350:g7607.
   PubMed Web of Science ®Google Scholar
• Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007;121:856–62.
   PubMed Web of Science ®Google Scholar
• Colhoun HM. SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in scotland: a study from the scottish diabetes research network epidemiology group. Diabetologia 2009;52:1755–65.
   PubMed Web of Science ®Google Scholar
• Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in sweden. Diabetologia 2009;52:1745–54.
   PubMed Web of Science ®Google Scholar
• Hemkens LG, Grouven U, Bender R, Gunster C, Gutschmidt S, Selke GW, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009;52:1732–44.
   PubMed Web of Science ®Google Scholar
• Karlstad O, Starup-Linde J, Vestergaard P, Hjellvik V, Bazelier MT, Schmidt MK, et al. Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies. Curr Drug Saf 2013;8:333–48.
   PubMedGoogle Scholar
• Bronsveld HK, Ter Braak B, Karlstad O, Vestergaard P, Starup-Linde J, Bazelier MT, et al. Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. Breast Cancer Res 2015;17:100. DOI: 10.1186/s13058-015-0611-2.
   PubMed Web of Science ®Google Scholar
• Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000;49:999–1005.
   PubMed Web of Science ®Google Scholar
• Osborne CK, Bolan G, Monaco ME, Lippman ME. Hormone responsive human breast cancer in long-term tissue culture: Effect of insulin. Proc Natl Acad Sci USA1976;73:4536–40.
   PubMed Web of Science ®Google Scholar
• Staiger K, Hennige AM, Staiger H, Haring HU, Kellerer M. Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells. Horm Metab Res 2007;39:65–7.
   PubMed Web of Science ®Google Scholar
• Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 2009;25:41–9.
   PubMed Web of Science ®Google Scholar
• Home P. Insulin therapy and cancer. Diabetes Care 2013;36Suppl:S240–4.
   Google Scholar
• Suissa S, Azoulay L, Dell'aniello S, Evans M, Vora J, Pollak M. Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia 2011;54:2254–62.
   PubMed Web of Science ®Google Scholar
• Habel LA, Danforth KN, Quesenberry CP, Capra A, Van Den Eeden SK, Weiss NS, et al. Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes. Diabetes Care 2013;36:3953–60.
   PubMed Web of Science ®Google Scholar
• Sturmer T, Marquis MA, Zhou H, Meigs JB, Lim S, Blonde L, et al. Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin. Diabetes Care 2013;36:3517–25.
   PubMed Web of Science ®Google Scholar
• Fagot JP, Blotiere PO, Ricordeau P, Weill A, Alla F, Allemand H. Does insulin glargine increase the risk of cancer compared with other basal insulins?: A french nationwide cohort study based on national administrative databases. Diabetes Care 2013;36:294–301.
   PubMed Web of Science ®Google Scholar
• Lim S, Stember KG, He W, Bianca PC, Yelibi C, Marquis A, et al. Electronic medical record cancer incidence over six years comparing new users of glargine with new users of NPH insulin. PLoS One 2014;9:e109433.
   Google Scholar
• Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, et al. Data resource profile: Clinical practice research datalink (CPRD). Int J Epidemiol 2015;44:827–36.
   PubMed Web of Science ®Google Scholar
• Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the general practice research database: a systematic review. Br J Clin Pharmacol 2010; Jan;69:4–14.
   PubMed Web of Science ®Google Scholar
• Boggon R, van Staa TP, Chapman M, Gallagher AM, Hammad TA, Richards MA. Cancer recording and mortality in the general practice research database and linked cancer registries. Pharmacoepidemiol Drug Saf 2013;22:168–75.
   PubMed Web of Science ®Google Scholar
• Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009;52:2499–506.
   PubMed Web of Science ®Google Scholar
• ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319–28.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Fonseca V, McGill JB, Riddle M, Halle JP, Hramiak I, et al. Similar risk of malignancy with insulin glargine and neutral protamine hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia 2009;52:1971–3.
   PubMed Web of Science ®Google Scholar
• Suissa S, Azoulay L. Metformin and the risk of cancer: Time-related biases in observational studies. Diabetes Care 2012;35:2665–73.
   PubMed Web of Science ®Google Scholar
• Patel CJ, Ioannidis JP. Placing epidemiological results in the context of multiplicity and typical correlations of exposures. J Epidemiol Community Health 2014;68:1096–100.
   PubMed Web of Science ®Google Scholar